ATHX · Athersys, Inc / New - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $5.33M | $5.51M | $1.44M | $5.63M | $17.35M | $3.71M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $65.03M | $71.08M | $62.99M | $39.05M | $38.66M | $27.84M |
| SG&A | $15.88M | $20.07M | $15.89M | $11.38M | $10.44M | $8.47M |
| Total Operating Expenses | $82.33M | $92.57M | $79.77M | - | - | - |
| D&A | $890.0K | $1.43M | $890.0K | $698.0K | $855.0K | $684.0K |
| Operating Income | ($77.01M) | ($87.06M) | ($78.33M) | ($45.49M) | ($25.05M) | ($33.28M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | $0 | - |
| Net Income | ($72.53M) | ($86.95M) | ($78.77M) | ($44.58M) | ($24.28M) | ($32.24M) |
| EPS - Basic | ($6.07) | ($0.42) | - | - | - | ($0.29) |
| EPS - Diluted | ($6.07) | ($0.42) | - | - | - | ($0.29) |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.04M | $37.41M | $51.55M | $35.04M | $51.06M | $29.32M |
| Accounts Receivable | $1.41M | - | - | - | $262.0K | $739.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $15.78M | - | - | - | $9.16M | $4.47M |
| Current Assets | $13.54M | $46.03M | $54.56M | $37.17M | $57.84M | $31.19M |
| Total Assets | $27.73M | $60.18M | $59.71M | $41.67M | $61.73M | $33.59M |
| Current Liabilities | $38.44M | $29.86M | $22.95M | $12.84M | $15.47M | $10.08M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($23.85M) | $16.37M | $31.36M | $23.27M | $43.12M | $23.38M |
| Retained Earnings | ($655.88M) | ($583.34M) | ($496.39M) | ($417.62M) | ($348.76M) | ($350.63M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($58.95M) | ($76.19M) | ($61.81M) | ($35.33M) | ($10.93M) | ($24.02M) |
| Investing Cash Flow | ($262.0K) | ($1.36M) | ($1.16M) | ($579.0K) | ($1.07M) | ($285.0K) |
| Financing Cash Flow | $30.84M | $63.41M | $79.48M | $19.89M | $3.72M | $38.87M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -1446.2% | -1578.9% | -5439.7% | -807.5% | -144.4% | -897.6% |
| EBITDA margin | -1429.5% | -1553.0% | -5377.9% | -795.1% | -139.4% | -879.2% |
| Net margin | -1362.1% | -1577.0% | -5469.8% | -791.4% | -140.0% | -869.5% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | 1221.2% | 1289.1% | 4374.6% | 693.1% | 222.8% | 750.8% |
| SG&A / Revenue | 298.3% | 363.9% | 1103.3% | 202.0% | 60.2% | 228.3% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -261.6% | -144.5% | -131.9% | -107.0% | -39.3% | -96.0% |
| Return on equity | 304.1% | -531.2% | -251.1% | -191.6% | -56.3% | -137.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.35 | 1.54 | 2.38 | 2.90 | 3.74 | 3.09 |
| Quick ratio | 0.35 | 1.54 | 2.38 | 2.90 | 3.74 | 3.09 |
| Cash ratio | 0.24 | 1.25 | 2.25 | 2.73 | 3.30 | 2.91 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -1.16 | 3.68 | 1.90 | 1.79 | 1.43 | 1.44 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.19 | 0.09 | 0.02 | 0.14 | 0.28 | 0.11 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 97d | - | - | - | 6d | 73d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -3.4% | 282.9% | -74.4% | -67.5% | 367.8% | -78.6% |
| Revenue CAGR (3y) | -1.9% | -31.8% | -27.0% | -31.3% | 13.2% | 31.7% |
| Revenue CAGR (5y) | 7.5% | -20.5% | -34.5% | 28.3% | 48.1% | -15.7% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 11.5% | -11.1% | -72.2% | -81.6% | 24.8% | -121.5% |
| Net income growth (YoY) | 16.6% | -10.4% | -76.7% | -83.6% | 24.7% | -110.2% |
| EPS growth (YoY) | -1345.2% | - | - | - | - | -61.1% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -47.8% | 34.8% | -46.0% | 84.4% | 109.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$5.51M totalService$5.23M · 94.9%
Product$283.0K · 5.1%
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ATHERSYS against the 5 most active filers in the same SIC group.